前列腺水刀消融术治疗有症状的良性前列腺增生:1年结果
这项前瞻性单臂多中心II期试验在澳大利亚和新西兰的3个中心纳入21例50至80岁、经尿动力学检查确诊为中重度下尿路症状的男性,行影像引导下的水刀消融术。1年随访显示,国际前列腺症状评分(I-PSS)从基线23.0改善至12个月时的6.8(p<0.0001),最大尿流率从8.7升至18.3 ml/s(p<0.0001),前列腺体积从57 ml降至35 ml(p<0.0001),无重要围手术期不良事件,未出现尿失禁且性功能保留。作者认为该II期研究为水刀消融术治疗有症状良性前列腺增生提供了早期安全性和有效性证据。
要点
- 水刀消融术后12个月I-PSS从基线23.0降至6.8(p<0.0001)。
- 最大尿流率从基线8.7升至18.3 ml/s(p<0.0001)。
- 前列腺体积从基线57 ml降至35 ml(p<0.0001),无重要围手术期不良事件。
核心结论
- 这项II期研究为水刀消融术治疗有症状良性前列腺增生提供了早期安全性和有效性证据。
研究设计与样本
- 前瞻性、单臂、多中心试验,在澳大利亚和新西兰共3个中心开展,随访1年。
- 纳入21例50至80岁、经尿动力学检查确定为中重度下尿路症状的男性,均行影像引导下水刀消融术。
主要发现
- 21例男性平均年龄69.7岁(范围62至78),前列腺体积57.2 ml(范围30至102)。
- 手术时长平均38分钟,水刀消融治疗时间平均5分钟;除1例外所有受试者仅留置导尿管1天,21例中19例术后次日出院。
- 最大尿流率时逼尿肌压力从基线65 cm H2O降至6个月时39 cm H2O(p<0.0027)。
- 前列腺体积从基线57 ml降至35 ml(p<0.0001)。
- 平均I-PSS评分从基线23.0改善至12个月时6.8(p<0.0001),最大尿流率从8.7升至18.3 ml/s(p<0.0001);无重要围手术期不良事件,未出现尿失禁且术后性功能保留。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to establish the safety and effectiveness of aquablation, a novel, image guided, robotic assisted, water jet tissue ablation technology, for the treatment of benign prostatic hyperplasia. MATERIALS AND METHODS: We performed a prospective, single arm, multicenter trial at a total of 3 centers in Australia and New Zealand with 1-year followup. Participants were men 50 to 80 years old with moderate to severe lower urinary tract symptoms as determined by urodynamics. All patients underwent aquablation under image guidance. Primary end points included procedural and perioperative safety. The main clinical end point was the change from baseline in I-PSS (International Prostate Symptom Score). Other secondary end points included uroflow measures, prostate volume on transrectal ultrasound and detrusor pressure. Detrusor pressure at maximum flow was only measured at 6 months. RESULTS: A total of 21 men underwent aquablation at a mean age of 69.7 years (range 62 to 78). Prostate volume was 57.2 ml (range 30 to 102). Procedural duration averaged 38 minutes with a mean aquablation treatment time of 5 minutes. All but 1 subject were catheterized for 1 day only and 19 of 21 were discharged home the day after the procedure. Detrusor pressure at maximum flow decreased from 65 cm H2O at baseline to 39 cm H2O at 6 months (p <0.0027). Prostate volume decreased from 57 ml at baseline to 35 ml (p <0.0001). Mean I-PSS score improved from 23.0 at baseline to 6.8 at 12 months (p <0.0001) and maximum urinary flow increased from 8.7 to 18.3 ml per second (p <0.0001). There were no important perioperative adverse events. No urinary incontinence developed and sexual function was preserved postoperatively. CONCLUSIONS: This phase II study provides early evidence to support the safety and effectiveness of aquablation for symptomatic benign prostatic hyperplasia.
引用
- Gilling P, Anderson P, Tan A, et al. Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: 1-Year Results. J Urol. 2017. PMID: 28111300. doi:10.1016/j.juro.2017.01.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。